These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33655632)

  • 1. Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
    Ni J; Si XY; Zhang L
    Thorac Cancer; 2021 Apr; 12(8):1244-1247. PubMed ID: 33655632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation.
    Wu Y; Ni J; Chang X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jul; 11(7):2051-2055. PubMed ID: 32458584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
    Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.
    Luo Y; Yao B; Huang P; Zhao Y; Chen J
    Ann Palliat Med; 2021 Dec; 10(12):12906-12910. PubMed ID: 35016465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.
    Wang L; Wu Y; Ren Z; Chu X; Chen J; Liu L; Zhao J; Yu X; Xie M; Su C
    Cancer Med; 2024 Jun; 13(12):e7335. PubMed ID: 38923311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
    Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
    BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
    Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report.
    Zhao H; Yang H; Yu X; Feng H; Yang F
    Anticancer Drugs; 2022 Jun; 33(5):509-512. PubMed ID: 35324516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib in
    Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
    J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.
    Lee Y; Lee B; Choi YL; Kang DW; Han J
    Mod Pathol; 2024 Jun; 37(6):100490. PubMed ID: 38588887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
    Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
    J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.
    Gao Z; Xu J; Wang Y; Wu J; Sun T
    Front Oncol; 2021; 11():715554. PubMed ID: 34722261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
    Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
    Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
    Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
    Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
    Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasąg B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S
    J Thorac Oncol; 2019 Jun; 14(6):1086-1094. PubMed ID: 30825613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.